why choose us

First received: July 16, 2024

Clinical Trial: Complement C5 mAb in the Treatment of Anti-GBM Disease

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Autoimmune Diseases

Study Type: INTERVENTIONAL


Official Title: A Single Center, Open-label, Single Arm Phase II Trial of the Efficacy and Safety of Complement C5 Monoclonal Antibody in the Treatment of Anti-glomerular Basement Membrane Disease

Brief Summary: Anti-GBM disease is the most severe form of glomerulonephritis.Despite of the standard treatment including plasmapheresis and immunosuppressant, 70% of the patients still go into end-stage kidney disease.Complement has been shown to participate in the pathogenesis of anti-GBM disease.This study aims to the investigate the therapeutic effects and safety of C5 monoclonal antibody in the treatment of anti-GBM disease.

Read more